Document is current
Any future updates will be listed below
-
Authors
Di Nitto, Cesare
Ravazza, Domenico
Gilardoni, Ettore
Look, Thomas
Sun, Miaomiao
Prodi, Eleonora
Moisoiu, Vlad
Pellegrino, Christian https://orcid.org/0000-0001-7898-9988
Manz, Markus G.
Puca, Emanuele
Weller, Michael
Weiss, Tobias https://orcid.org/0000-0002-5533-9429
Neri, Dario
De Luca, Roberto https://orcid.org/0000-0001-7519-8689
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00091338 at ClinicalTrials.govnct00492440 at ClinicalTrials.govDocuments that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
nct00062049 at ClinicalTrials.govDocuments that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
nct02938299 at ClinicalTrials.govDocuments that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
nct03567889 at ClinicalTrials.govDocuments that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9501
Universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44<sup>+</sup> CD8<sup>+</sup> T cells in tumor-draining lymph nodes to enhance antitumor immunity
https://doi.org/10.1136/jitc-2025-011944
nct04362722 at ClinicalTrials.govDocuments that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
Universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44<sup>+</sup> CD8<sup>+</sup> T cells in tumor-draining lymph nodes to enhance antitumor immunity
https://doi.org/10.1136/jitc-2025-011944
nct05329792 at ClinicalTrials.govDocuments that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
Intralesional administration of L19IL2/L19TNF in high-risk locally advanced basal cell carcinoma or cutaneous squamous cell carcinoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.tps9617
nct02938299 at ClinicalTrials.govDocuments that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
nct03567889 at ClinicalTrials.govDocuments that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9501
Universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44<sup>+</sup> CD8<sup>+</sup> T cells in tumor-draining lymph nodes to enhance antitumor immunity
https://doi.org/10.1136/jitc-2025-011944
Documents that mention this clinical trial
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
https://doi.org/10.1136/jitc-2023-008504
Universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44<sup>+</sup> CD8<sup>+</sup> T cells in tumor-draining lymph nodes to enhance antitumor immunity
https://doi.org/10.1136/jitc-2025-011944
- License Information
